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Abstract The long-term use of hypotensive drugs may cause
side effects, including impaired glucose metabolism and min-
eral status. This study tested the hypothesis that some hypo-
tensive drugs can affect tissular chromium levels and indices
of glucose metabolic and antioxidant potential in rats. The
experiment was performed on 40 male spontaneously hyper-
tensive rats (SHRs), which were assigned to five groups:
control (C), with perindopril (PR), with metoprolol (MT),
with indapamide (ID), and with amlodipine (AM). All rats
were provided ad libitum standard diet (with or without drugs)
and distilled water for 45 days. Glucose and insulin levels,
along with total antioxidant status (TAS) and concentrations
of TNF-alpha and C-reactive protein, were assayed in serum.
Chromium concentrations in the liver and kidney were deter-
mined using the flame atomic absorption spectrometry meth-
od. Detailed statistical analysis was performed using Statistica
for Windows 10.0 (StatSoft, Poland). One-way analysis of
variance (ANOVA), followed by a post hoc Tukey test, was
used to compare the data between groups. Treatment with
indapamide and amlodipine resulted in significantly higher
chromium concentrations in the liver and kidney (AM) of the
rats, compared with the control group. A markedly higher
concentration of glucose was found in the ID group.
Treatment with amlodipine significantly increased TAS levels
in serum and decreased TNF-alpha concentration in serum of
the rats. A significant positive correlation between chromium
concentration in tissues and serum TAS level was observed, as
was a significant negative correlation between chromium
concentration in the kidneys, and TNF-alpha and glucose
levels in serum. In conclusion, the administration of
amlodipine may lead to an increase in chromium accumula-
tion in the internal organs, which is associated with increased
antioxidant status and suppression of the inflammatory re-
sponse of cells in SHRs.
Keywords Antihypertensive drugs . Chromium . Glucose
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Introduction
Recently, the interaction of active components of drugs with
certain nutrients has been a matter of increasing interest. Due
to their complex chemical structures and properties, the hypo-
tensive drugs used in the treatment of hypertension may have
broader biological activity, unrelated to their therapeutic target
actions. Of particular interest is the possibility of interaction
between hypotensive drugs and essential minerals, leading to
the increase or decrease of mineral availability, storage, and
excretion, which in consequence may affect the mineral
status of related systems and of the body as a whole.
Antihypertensive drugs could influence the metabolism of
minerals in many ways, from intestinal absorption to bioavail-
ability and elimination. In clinical and experimental studies, it
has been observed that treatment with angiotensin-converting
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enzyme inhibitors (ACE-I) and some diuretics may result in
deficits of magnesium, potassium, and zinc [1–3]. Moreover,
treatment with certain antihypertensive drugs, such as thia-
zides and β-blockers, may impair carbohydrate metabolism
and lead to an increased incidence of diabetes mellitus in
hypertensive patients [4, 5]. On the other hand, it has also
been found that amlodipine (a long-acting calcium-channel
blocker) improved insulin sensitivity in essential hypertensive
patients and exhibited antioxidant and anti-inflammatory
properties [6, 7]. However, it is not known whether the effects
of antihypertensive drugs on glucose metabolism are associ-
ated with the level of chromium in the body. Chromium(III)
has a documented role in the carbohydrate, lipid, and protein
metabolisms. Trivalent chromium has been shown to lower
oxidative stress and to improve glucose and lipid metabolism,
but the mechanisms of its action on the molecular level are not
fully understood [8]. There are no reliable biomarkers of the
body’s Cr status [9]. Since Cr is stored mainly in the liver and
the kidneys, these tissues are often used to estimate the major
reserves of the element in laboratory animals.
Considering the above facts, we tested the hypothesis that
hypertensive drugs can affect chromium status, glucose me-




This study was approved by the local bioethics committee for
animal studies (approval no. 49/2009).
The experiment was performed on male SHRs (8 weeks
old), derived from Wistar Kyoto rats with elevated blood
pressure at the Kyoto School of Medicine. The rats were
purchased from Charles River Laboratories, Germany. The
rats adapted to laboratory conditions during the first 5 days.
The mean body mass of the rats was 195±21 g. The animals
were housed individually in stainless steel cages coated with
metal-free enamel and kept under controlled room conditions:
temperature (21 °C), humidity (55–65 %), and 12/12 h light/
dark cycle.
Experimental Design
Forty animals were randomly assigned to five groups of eight
rats each: the control group (C), a group with perindopril (PR),
a group with metoprolol (MT), a group with indapamide (ID),
and a group with amlodipine (AM). All rats were fed a
standard diet (maintenance diet for rats 1320, Altromin),
whose full composition is presented in Table 1. In the diet of
the noncontrol groups, perindopril, metoprolol, indapamide,
and amlodipine were added at a rate of 0.2, 3.0, 0.03, and
0.2 mg/kg body mass of rat, respectively. The drug was
administered in the diet, and fresh solutions were prepared
every day. The drug concentrations were adjusted so that the
doses (calculated as milligrams per kilogram per day) were
kept constant, regardless of dietary intake and body weight.
The intake of the diet was monitored daily. The rats were
weighed once a week.
The animals are allowed to eat diet and drink distilled water
for 45 days “ad libitum”.
Tissue and Serum Collection
At the end of the experimental period, the animals were
weighed and anesthetized with a sodium thiopental injection
(40 mg/kg body weight). Blood and tissues were collected
from the rats following 12 h of fasting. The liver and kidney
were dissected, weighed, and stored frozen (−80 °C) for
analysis for chromium content. The blood samples were col-
lected by cardiac puncture in serum-separated tubes to obtain
serum. The coagulated blood was left to clot at room temper-
ature for 30 min and then centrifuged for 15 min at 2,000 rpm
at 4 °C; the supernatant fluid was then separated and stored
frozen (−80 °C) for analysis.
Biochemical Measurements
The concentration of glucose in the blood serum was estimat-
ed using the glucose oxidase method [10]. Serum insulin was
determined using the radioimmunoassay method with a rat
insulin RIA kit (Insulin RIA Kit, Linco Research, USA).
Serum TNF-alpha was measured by enzyme immunoassay
(enzyme-linked immunosorbent assay; R&D Systems, Inc.,
Minneapolis, MN, USA). Total antioxidant status (TAS) was
measured using a TAS Randox kit (Randox Laboratories, Ltd,
Crumlin, UK) and spectrophotometry (SPECORDM40; Carl
Zeiss, Jena, Germany). Serum C-reactive protein (CRP) level
was determined by ELISA (R&D system, USA).
Determination of Chromium
The chromium content of the tissues was determined follow-
ing digestion in 65 % (w/w) spectra pure HNO3 (Merck) in a
Microwave Digestion System (MARS 5, CEM Corp., USA).
Thereafter, the concentrations of chromium in the mineral
solutions were measured using the atomic absorption spec-
trometry method (AAS-5, EA, Jenoptic). Chromium content
was determined at a wavelength of 357.9 nm. The accuracy of
the method was verified with certified reference materials
(bovine liver-trace elements, NIST-1577C, CERT) and proved
to be 93 %.
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Statistical Analysis
Detailed statistical analysis was performed using Statistica for
Windows 10.0 (StatSoft, Poland). The results were expressed
as arithmetic means with standard errors. One-way analysis of
variance (ANOVA) and a post hoc Tukey test were used to
compare the data between groups. The correlations between
biochemical variables were calculated using Pearson’s test
(with Pearson’s r coefficient). The significance was set at
the p <0.05 level.
Results
The results of the experiment are shown in Tables 2, 3, and 4.
The average intake of diet and chromium was comparable
across groups (Table 2). As can be seen from Table 3, the
treatment of the SHRs with hypotensive drugs (PR, MT, ID,
and AM) did not affect major glucose metabolism indices in
serum, such as glucose, insulin, and homeostasis model of
assessment—insulin resistance (HOMA IR), except in the
case of ID, where glucose levels increased (by 11.5 %).
The treatment of the rats with the hypotensive drugs also
had no influence on the indices of antioxidant status and
proinflammatory factor (TNF-alpha) and CPR status in serum.
On the other hand, treatment of rats with AM brought about a
significant increase in serum TAS (of 158 %) accompanied by
a decline in TNF-alpha levels (of 53 %).
The treatment of rats with these drugs affected the tissular
chromium contents in a drug-dependent manner (Table 4).
While PR and MT brought about a slight (though not signif-
icant) increase in the hepatic and renal Cr contents, the effect
of ID and AM was appreciable. The ID and AM treatment
significantly increased hepatic Cr levels by 34 and 46 %,
respectively, whereas AM also increased the renal Cr content
by 83 % over the control value.
The relationships between the biochemical variables were
evaluated using Pearson’s correlation test (with Pearson’s r
Table 1 The composition of the
diet Ingredient Amount Ingredient Amount
Total energy (kcal/kg) 2,844 Biotin (μg/kg) 60
Total protein (% of energy) 24 Nicotinic acid (mg/kg) 36
Total fat (% of energy) 11 Pantothenic acid (mg/kg) 21
Total carbohydrate (% of energy) 65 Choline chloride (mg/kg) 600
Protein (g/100 g) 19 Calcium (g/kg) 9
Fat (g/100 g) 4 Phosphor (g/kg) 7
Fiber (g/100 g) 6 Magnesium (g/kg) 3
Vitamin A (IU) 1,500 Sodium (g/kg) 2
Vitamin D3 (IU) 600 Potassium (g/kg) 1
Vitamin B1 (mg/kg) 18 Iron (mg/kg) 165
Vitamin B2 (mg/kg) 12 Manganium (mg/kg) 75
Vitamin B6 (mg/kg) 9 Zinc (mg/kg) 70
Vitamin B12 (μg/kg) 24 Copper (mg/kg) 13
Vitamin C (mg/kg) 36 Iodium (mg/kg) 1.5
Vitamin K3 (mg/kg) 3 Selenium (mg/kg) 0.6
Vitamin E (mg/kg) 75 Cobalt (mg/kg) 0.3
Folic acid (mg/kg) 2 Chromium (mg/kg) 4.5
Table 2 Daily diet and chromium intake in rats
Groups
C (n =8) PR (n =8) MT (n =8) ID (n=8) AM (n =8)
Diet (g/day/rat) 23.5±1.1 24.2±1.0 24.0±0.9 24.3±0.9 23.9±1.1
Cr (mg/day/rat) 0.11±0.02 0.11±0.03 0.11±0.01 0.11±0.01 0.11±0.03
C control group, PR group with perindopril,MT group with metoprolol, ID group with indapamide, AM group with amlodipine, n number of rats in the
group
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coefficient). Statistically significant positive correlations were
found for the following parameters: liver and kidney Cr con-
tents and serum TAS (r =0.72, p <0.001; r =0.60, p =0.001),
respectively. Significant negative correlations were found be-
tween kidney Cr content and serum glucose levels (r =−0.34,
p =0.04) and the kidney Cr content and serum TNF-alpha (r =
−0.59 p =0.002; Figs. 1, 2, 3, and 4).
Discussion
In this study, an association between amlodipine in the diet of
SHR and increased levels of chromium in their tissues was
observed. Higher concentration of chromium in the liver and
kidney in the AM group was associated with higher TAS and
low TNF-alpha levels in serum of the rats. To our knowledge,
this is the first study evaluating the effects of antihypertensive
drugs on the level of chromium in SHRs.
The results of this study confirm the antioxidant and anti-
inflammatory effects of amlodipine. Some studies have found
that amlodipine has an anti-inflammatory effect by inhibiting
the production of TNF-alpha and NO [11]. It is suggested that
this beneficial activity of amlodipine is dependent on its
interaction with cholesterol and oxidants, and/or the
mechanism by which amlodipine regulates NO production
and its implications [12].
Koh et al. [13] found that amlodipine therapy significantly
reduced biomarkers of oxidant stress and improved glucose
metabolism, including increases in insulin sensitivity in hy-
pertensive patients. The antioxidative, anti-inflammation, and
antidiabetic effect of chromium(III) supplementation has been
also observed in experimental studies in rats [14–16].
These results have demonstrated that the administration of
amlodipine increases kidney and liver Cr stores, and that
indapamide elevates liver Cr stores alone, in comparison with
baseline values. The mechanism responsible for this phenom-
enon is unknown. There are various possibilities that could
alter the accumulation of this element in the internal organs.
In some studies, it has been found that antihypertensive
drugs disturb the homeostasis of electrolytes and other min-
erals through alterations in kidney or intestine mineral reab-
sorption, as well as by effecting changes in the reabsorption of
minerals from the system blood to the tissues [1, 3, 17]. The
mechanism involved in the change in the tissue chromium
concentration as a result of amlodipine treatment may be
similar. In the previous study, it was found that amlodipine
and indapamide affected the potential bioavailability of min-
erals from food in in vitro enzymatic digestion [18, 19]. The
Table 3 Biochemical parameters in rats
Parameter Groups
C (n =8) PR (n =8) MT (n =8) ID (n =8) AM (n =8)
Glucose (mmol/l) 6.1±0.3a 6.2±0.5a 5.9±0.6a 6.8±0.3b 6.1±0.3a
Insulin (pmol/l) 132.4±41.0 137.5±48.2 122.0±36.6 108.1 ±21.2 134.6 ±48.3
HOMA 5.01±1.43 5.60±2.31 4.32±1.47 4.47±0.85 5.15±1.77
TAS (mmol/l) 1.16±0.32a 1.12±0.20a 0.96±0.17a 1.59±0.24a 2.99±0.26b
TNF-alpha (ng/ml) 2.24±0.25b 2.17±0.24b 1.97±0.18b 2.31±0.16b 1.05±0.09a
CRP (ng/ml) 84.9±5.26 80.5±7.74 79.8±7.2 82.3±11.6 76.3±12.1
C control group, PR group with perindopril,MT group with metoprolol, ID group with indapamide, AM group with amlodipine, HOMA homeostasis
model of assessment—insulin resistance index, n number of rats in the group
a,b Significant differences between five groups (ANOVA test, p <0.05)
Table 4 Chromium concentration in tissues of rats (ng/g d.w.)
Tissue Groups
C (n =8) PR (n =8) MT (n =8) ID (n =8) AM (n =8)
Liver 603.5±86.3a 612.0±96.1a 613.5±95.5a 812.8±117.8b 881.7±126.7b
Kidney 369.3±38.0a 489.2±98.6a 468.2±105.9a 414.6±94.9a 673.9±92.6b
C control group, PR group with perindopril, MT group with metoprolol, ID group with indapamide, AM group with amlodipine, n number of rats in
group
a,b Significant differences between five groups (ANOVA test, p <0.05)
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increased concentration of Cr in the liver and kidneys may
result from increased gastrointestinal absorption of this ele-
ment in the presence of amlodipine (and indapamide, to a
lesser extent). Generally, dietary Cr is absorbed with very low
efficiency (0.4–2 %) [20], and the rate of its uptake depends
on the coupling ligand [21]. Commonly used forms of Cr in
supplements—including CrCl3, Cr(III) nicotinate, and
CrPic—are absorbed at only 0.5–1.3 % of the dose, while
the Cr complex with propionic acid (chemical formula
[Cr3O(O2CCH2CH3)6(H2O)3]
+, also called Cr3) is absorbed
with a very high efficiency of 40–60% [22]. The difference in
the degree of absorption is readily explained by the stability
and solubility of the cation in the physiological milieu. The
dietary Cr used in this experiment was present in an inorganic
form (CrCl3×6H2O), so its absorption was presumed to be
low (<1 %). It is possible that an active component of
amlodipine might somehow chelate dietary Cr, thus improv-
ing its absorption and further storage in the internal organs.
Another possible explanation of the increased hepatic and
renal Cr levels found in this study is the formation of Cr-
drug complexes that are trapped in the tissular matrix.
Amlodipine may have also reduced Cr urinary excretion,
thus leading to higher retention in the body. Finally, the drugs
tested here (amlodipine and indapamide) might affect the
distribution of chromium in the body. In a recent report [23],
the effects of prednisolone (a glucocorticoid) on Cr distribu-
tion in mice fed a high-fat diet was demonstrated. In that
study, prednisolone treatment lead to reduced Cr levels in
insulin-sensitive tissues (liver, muscle, and fat), while tending
to elevate Cr levels in the thigh bone.
Whichever of these mechanisms occurred in this study, the
higher hepatic and renal Cr levels were associated with in-
creased serum TAS values. Significant moderate correlations
were found for hepatic and renal Cr levels and serum TAS,
suggesting that Cr plays some role in supporting antioxidant
potential. The mechanisms of its action are not fully
understood.
Some reports indicate that Cr(III) supplementation can
decrease oxidative stress and proinflammatory cytokines
(such as TNF-alpha, IL-6, and CRP) in animal and human
studies [14, 24]. In this study, the possible antioxidant prop-








Fig. 1 Correlation (Pearson’s r)
between TAS level in serum and









Fig. 2 Correlation (Pearson’s r)
between TAS level in serum and
chromium concentration in
kidney of rats
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with amlodipine, because of the antioxidant and anti-
inflammatory activities of amlodipine.
The effect of chromium on inflammation may indirectly
affect glucose metabolism. It is known that TNF-alpha, IL-6,
and CRP play an important role in insulin resistance and the
vascular inflammation process through their multiple actions
[25, 26]. Rui et al. [27] found that TNF-alpha reduces insulin-
stimulated receptor tyrosine kinase activity at low concentra-
tions and may also decrease the expression of the insulin
receptor IRS-1 and Glut-4 at higher concentrations, while also
increasing the phosphorylation of serine 307 in IRS-1, thus
impairing its ability to bind to the insulin receptor and initiate
downstream signaling.
In this study, a moderate negative correlation was observed
for the kidney Cr level and the serum glucose level, supporting
the opinion that Cr is involved in the regulation of glucose
homeostasis. A number of studies in both diabetic animals and
diabetic human patients have reported that chromium supple-
mentation may be beneficial, as demonstrated by decreased
blood glucose, glycosylated hemoglobin, and cholesterol
values, or by decreased insulin requirements following chro-
mium supplementation [15, 28, 29].
Conclusions
This study showed that the administration of hypotensive
drugs, and in particular amlodipine, significantly increased
hepatic and renal Cr levels and is associated with increased
serum TAS value and decreased levels of the inflammatory
marker TNF-alpha in serum in SHRs. In addition, significant
positive correlations were observed between hepatic and renal
Cr levels and serum TAS, and significant negative correlations
were seen between the renal Cr level and serum TNF-alpha
and serum glucose levels in SHRs treated with hypotensive
drugs.
It is hypothesized that the administration of hypertensive
drugs, in particular of amlodipine, may lead to increases in
chromium accumulation in the internal organs, which in turn
can mediate (increasing antioxidant status) and suppress the
inflammatory response of cells. However, elucidation of the
exact mechanisms responsible for these effects requires fur-
ther investigation.
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